A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells

BACKGROUND: The use of “off-the-shelf” cellular therapy products derived from healthy donors addresses many of the challenges associated with customized cell products. However, the potential of allogeneic cell products to produce graft-versus-host disease (GVHD), and their likely rejection by host a...

Descripción completa

Detalles Bibliográficos
Autores principales: Quach, David H., Becerra-Dominguez, Luis, Rouce, Rayne H., Rooney, Cliona M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657103/
https://www.ncbi.nlm.nih.gov/pubmed/31340822
http://dx.doi.org/10.1186/s12967-019-1988-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657103/
https://www.ncbi.nlm.nih.gov/pubmed/31340822
http://dx.doi.org/10.1186/s12967-019-1988-y

Ejemplares similares